This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
The reason reading a preclinical wound-healing model keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.
This follows post #29 rather than contradicting it.
Reading a preclinical wound-healing model is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
Anecdote is the whole of the human evidence base here, and this community's convention is to say so rather than to aggregate anecdotes into something that sounds like data.
On balance I think that is right, and I would not bet much on it.
Nobody has said the unglamorous part of reading a preclinical wound-healing model yet, so: most of the variation is explained by things that are boring to write about and easy to check.
Coming back to post #33, because the follow-up matters more than the original answer.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
Post #37 describes the usual case. This is about the unusual one.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.
If this contradicts something upthread, the upthread version may well be the better one.
An update on my earlier reading a preclinical wound-healing model post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
Second this, and I would have said it less carefully.
Narrowing post #41, because the general version has more than one answer.
For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.
Everything in post #40 holds. The case it does not cover is the one I have.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
Reading a preclinical wound-healing model would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Post #44 put the caveat in the right place and I want to underline it.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
The arithmetic in post #46 is right; the assumption feeding it is the part to check.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
I keep a log of this specifically because memory is unreliable about it.
Reading a preclinical wound-healing model: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
An observation about reading a preclinical wound-healing model that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Answering the question post #51 raises rather than the one it answers.
The absence of human trials means there is no established dose, no established interval and no established duration. Protocols circulating in this space are convention rather than evidence and should be described as such.
The number is defensible. The precision I gave it is not.
The arithmetic in post #51 is right; the assumption feeding it is the part to check.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.
That is clearer than the version I had in my head. Thank you.
Two sentences on reading a preclinical wound-healing model and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.
Adding the measurement that post #55 says would settle it.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
That distinction has done more work for me than anything else in this category.
Post #55 and I disagree about the size of the effect, not about the direction.
Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.
Taking post #59 at face value and following it one step further.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.